Studies of cannabinoid metabolites — a free radical immunoassay  by Cais, Michael et al.
Volume 55, number 1 FEBS LETTERS July 1975 
STUDIES OF CANNABINOID METABOLITES  - A FREE RADICAL IMMUNOASSAY 
Michael CAIS*, S. DANI, Y. JOSEPHY and A. MODIANO 
Department of Chemistry, Technion-lsrael Institute of Techl~ology, Haifa, Israel 
H. GERSHON 
School of Medicine, Technion-Israel Institute of Technology, Haifa, Israel 
and 
R. MECHO! ILAM 
School of Pharmacy, Hebrew University, Jerusalem, Israel 
Received 22 May 1975 
1. Introduct ion 
The societal implications of the growing use of 
cannabis drugs finds expression also in the noticeable 
recent expansion of cannabinoid research in bio- 
logical, chemical, pharmacological and medical 
sciences [ 1 ]. Rather surprisingly, however, there have 
been relatively few reports of attempts to develop 
immunological techniques for the study and identifi- 
cation of cannabinoid metabolites. One reason for 
this may be due to the serious difficulties which have 
been encountered in the production of anti-canna- 
binoid antibodies [2]. A radioimmune assay for 
A1 -tetrahydrocannabinol (zzl -THC = A9.THC) recently 
described [3] utilized goat antiserum obtained [4] 
against a mixture of isomers of azo -A1 -THC. The au- 
thors claim [3] potential use of their method for the 
detection of THC in the plasma of chronic marijuana 
users, if the assay is carried out within 15 rain after 
the smoking act. A similar time-limit for the detection 
of THC in plasma pplies to a recently described [5] 
assay employing a combination of gas liquid chroma- 
tography and mass spectrometer analysis. Another 
radioimmune assay, using a sheep antisera nd [a H] 
THC has been reported [6] to detect THC in the 
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blood or urine of a person following the smoking of 
a single cigarette impregnated with 5 mg of pure THC. 
In this communication we wish to report he syn- 
thesis of protein conjugates with ~6.tetrahydrocan. 
nabinol (A6.THC) derivatives II-V, the production of 
specific antibodies to the II to V-haptenic groups, the 
preparation of spin-labelled haptens, VII-IX, (fig. 1) 
and the use of these materials for the detection of 
cannabinoid metabolites by a free-radical immunoassay, 
(fig.2). These results have been obtained as a part of 
a systematic study undertaken to determine the capa- 
bility of the cannabinoid structural skeleton to trigger 
specific antibody formation. In addition, in view of 
previously reported ifficulties [2] we have been 
aiming at the production of optimal antisera prepara- 
tions for suitable general use in immunoassays. 
2. Materials and methods  
The starting material, A6 -THC, I, was obtained by 
previously described methods involving solvent 
extraction of hashish, chromatographic purification 
and appropriate chemical transformations [ 1 ]. The 
cannabinoid acids II to VI were prepared by stan- 
dard organic synthesis procedures and all had satis- 
factory elementary and spectroscopic analyses. 
The haptens (fig. 1) were coupled to two immuno-  
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Fig.1. Derivatives of zX6-THC coupled to protein carders (BSA and OVA, n = number of hapten molecules per protein molecule) 
and to a stable free radical (3-amino-2,2,5,5-tetramethylpyrrolidine-l-oxyl) 
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logically non-crossreacting carriers, bovine serum al- 
bumin (BSA) and ovalbumin (OVA), by the mixed 
anhydride procedure using isobutylchlorotormate in 
dimethyl formamide. The degree of conjugation, 
(fig. 1) was determined by differential u.v. analysis. 
Rabbits were immunized by multiple subcutaneous 
injections along the flank, nape and rump with an 
emulsion of complete Freund's adjuvant and the 
appropriate cannabinoid-BSA conjugate. Bleeding was 
carried out prior to immunization (for normal serum) 
and at weekly intervals ubsequent to immunization. 
Booster injections were given at regular six-weekly 
intervals. Sera from bleedings between boosters were 
pooled. Immunoglobins were preparated from pooled 
antisera nd normal sera by precipitation i ammo- 
nium sulfate followed by dialysis against 0.01 M phos- 
phate buffered saline, pH 7.3 (PBS). Immunological 
assays were carried out using both classical precipitin 
reactions with hapten inhibition of precipitation and 
free radical immunoassay techniques. The precipitin 
curves obtained in the quantitative assays howed that 
the antisera produced contained antibodies to the 
hapten as well as to the carrier (BSA). This was de- 
monstrated by the precipitation of BSA with or 
without hapten conjugation, by the precipitation of 
hapten-OVA conjugate by antisera which did not 
recognize the OVA carrier alone and by inhibitiol, of 
precipitation of hapten-OVA by free hapten. The 
normal sera prior to immunization were not found to 
react with any of the antigens tested. The amount of 
specific anti-cannabinoids antibodies in various era 
was found to vary from 0.3 mg/ml to 1.9 mg/ml. 
The spin labelled haptens VII-IX, prepared by 
coupling the respective carboxylic acid derivatives 
with 3-amino-2,2,5,5-tetramethylpyrrolidine- 1-oxyl 
(using dicyclohexyldiimide as coupling reagent), were 
employed to characterize the anti-cannabinoid anti- 
bodies by a competitive binding free-radical technique 
analogous to that already described for anti-morphine 
antibodies [7]. A solution containing appropriate 
known amounts of specific 3,-globulin and spin-labelled 
hapten was titrated with increasing amounts of the 
unlabelled hapten. The amount of competitively dis- 
placed spin-labelled hapten was monitored by a Varian 
E.-4 electron spin resonance (ESR) instrument. A 
typical curve obtained in the determination f anti- 
serum specificity isshown for anti-hapten III (fig.2) 
together with cross-reactivity curves measured for 
closely related cannabinoids. 
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Fig.2. Mobilization of antibody bound-spin-labelled 7-nor-1- 
earboxy-3'-methoxy-zx6 -THC(lid by increasing amounts of 
unlabelled THC derivatives. (.) 7-nor-l-carboxy-3'-methoxy- 
zx~-THC (III); (+) 7-nor-l-earboxyvinyl-3'-methoxy-zx6-THC (V); 
(z~) 7.hydroxy.3'.methoxy_~6.THC; (o) 3'-O-carboxymethyl- 
A6-THC (IV); (x) Codeine. 
3. Results and discussion 
Recent reviews [1,8] on metabolic studies with 
cannabinoids show that, whilst a number of important 
facts have become known, the general picture is still 
rather confused and controversial. This has imposed 
restrictions on our choice of haptens for the produc- 
tion of anti-cannabinoid antibodies. Our selection 
was governed in the first stage by structural analogies 
to identified THC metabolites. Subsequently we 
aimed at collecting information on the ability of the 
various cannabinoid features to trigger specific anti- 
body production. 
Data obtained so far indicate that antibodies elicited 
with hapten-III antigens possess greater affinity than 
those produced with antigens carrying haptens IV or V, 
Acid III bears a close structural relationship to 7-hy- 
droxy-Al -THC which has been found in the urine of 
marijuana smokers [9]. Metabolic oxidation of the 
7-methyl function to a carboxyl group, leading to 
analogs of III, is known [10]. 
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the same urines spiked with 0.7 tag/ml of the acid 
derivative III. The mirror-image like symmetry, of the 
two parts of the histogram, is a gratifying pictorial 
outcome of the fact that every spiked urine sample 
gave a higher ESR signal than its non-spiked counter- 
part. 
Preliminary free radical immunoassay experiments 
with extracts from ten human urines collected from 
both casual (less than once a month) and habitual 
(at least once week) hashish smokers indicate that a 
positive, significant increase in the ESR signal should 
occur with the samples given any time, from 5 to 72 
hr after the smoking of hashish. Urine samples collected 
between 0.5 -2.5 hr subsequent to hashish smoking 
did not give positive tests. A larger number of urine 
samples from hashish users must be tested before the 
scope of our assay can be fully assessed. We have been 
having some difficulties in obtaining such samples. 
This relationship also finds expression in the degree 
of cross-reactivity b  7-hydroxy-3'-methoxy-A 6-THC 
in the mobilization of the antibody bound spin-label- 
led-acid III (fig.2). 
Anti-hapten II antibodies also appear to be of satis- 
factory affinity and specificity. However, some uncer- 
tainty must be attached to the interpretation of results 
obtained from work with II due to the reported insta- 
bility of the latter (II is known to undergo facile 
decarboxylation). We are currently investigating hapten 
VI which retains all the functional groups of ~6.THC 
(including the phenolic group) and hopefully will not 
exhibit the instability reported for II. 
The applicability of these results to urine analysis 
for cannabinoid metabolites was checked by spiking 
normal urines with the A6-THC derivative, III, and 
measuring the degree of detection with our reagents. 
Variations in the ESR signal of 100 randomly collected 
normal urines are given on the left side of the histogram 
in fig.3. On the right side of the histogram are shown 
the variations in the ESR signal obtained irectly with 
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